Table 1.

Summary of the most common AEs and SAEs associated with the treatment with Opdualag compared to Nivolumab alone in the RELATIVITY-047 clinical trial (NCT03470922).

		Opdualag (n = 355)	Nivolumab (n = 359)
AEs	Musculoskeletal pain	54.6%	33.1%
	Fatigue	29.3%	20.6%
	Asthenia	13.5%	9.2%
	Pyrexia	12.4%	9.2%
	Headache	18.0%	13.1%
	Cough	14.1%	10.6%
	Rash	17.4%	13.6%
	Pruritus	24.8%	17.3%
	Diarrhea	23.1%	17.3%
	Nausea	17.7%	16.4%
	Constipation	11.0%	7.0%
	Decreased appetite	15.5%	7.5%
	Anaemia	14.1%	10.3%
	Increased AST	9.9%	4.7%
	Increased ALT	10.1%	5.85%
	Hypothyroidism	16.3%	13.1%
SAEs	Anaemia	1.4%	1.1%
	Acute myocardial infarction	1.1%	0.6%
	Myocarditis	1.1%	0.3%
	Adrenal insufficiency	1.4%	0.0%
	Colitis	1.4%	0.3%
	Diarrhea	1.1%	0.8%
	General health deterioration	0.6%	1.7%
	Pyrexia	0.9%	1.4 %
	Pneumonia	1.4%	0.8%
	Urinary tract infection	0.9%	1.7%
	Back pain	1.1%	0.6%
	Malignant neoplasm progression	11.0%	13.1%
	Metastases to central nervous system	1.1%	0.8%
	Pneumonitis	1.1%	0.3%